A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

NCT05500222 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

700

Enrollment

INDUSTRY

Sponsor class

Conditions

NASH
Cirrhosis, Liver

Interventions

DRUG: Resmetirom
DRUG: Placebo

Sponsor

Madrigal Pharmaceuticals, Inc.